These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31686847)

  • 1. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
    An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
    Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
    Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
    Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.
    Xu F; Xia ML; Pan HY; Pan JW; Shen YH
    World J Clin Cases; 2022 Jun; 10(17):5916-5922. PubMed ID: 35979118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.
    Wu JY; Shih JY
    Onco Targets Ther; 2016; 9():6137-6145. PubMed ID: 27785061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.
    Valcárcel S; Villanueva N; Álvarez C; Esteban E
    Anticancer Drugs; 2024 Aug; 35(7):638-640. PubMed ID: 38513159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
    Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
    Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
    Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
    Long X; Qin T; Lin J
    Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of afatinib in patients with NSCLC harboring novel uncommon
    Christopoulos P; Herster F; Hoffknecht P; Falk M; Tiemann M; Kopp HG; Althoff A; Stammberger A; Laack E
    Front Oncol; 2024; 14():1347742. PubMed ID: 38769948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare
    Zöchbauer-Müller S; Kaserer B; Prosch H; Cseh A; Solca F; Bauer MJ; Müllauer L
    Front Oncol; 2020; 10():593852. PubMed ID: 33575211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Lung Adenocarcinoma Patient With a Rare
    Wei Y; Cui Y; Guo Y; Li L; Zeng L
    Front Oncol; 2021; 11():700345. PubMed ID: 34178699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Chan RT
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():7-9. PubMed ID: 29508940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib for the treatment of metastatic non-small cell lung cancer.
    Joshi M; Rizvi SM; Belani CP
    Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.
    Zhang Y; Shen JQ; Shao L; Chen Y; Lei L; Wang JL
    World J Clin Cases; 2021 Sep; 9(27):8220-8225. PubMed ID: 34621884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.